

## Brand Institute & Drug Safety Institute partnered on approximately 60% of INN and USAN approvals in 2015

The 62nd Consultation on International Nonproprietary Names (INN) for Pharmaceutical Substances will take place from April 12-15th, 2016. Early submission deadline is January 8th, 2016. After this date an additional 30 submissions received before February 8th will be accepted for review. The deadline for outstanding INN requests and rebuttals is February 15th, 2016.

### Brand Institute is Proud to Have Partnered on these 40 New Nonproprietary Name Approvals!

|                        |                           |                   |
|------------------------|---------------------------|-------------------|
| amiselimod             | indusatumab               | sapanisertib      |
| avoralstat             | indusatumab vedotin       | seletalisib       |
| axalimogene filolisbac | isatuximab                | somavaratan       |
| brolocizumab           | landelumab                | soravtansine      |
| cinhyaluronate sodium  | lanopepden                | susoctocog alfa   |
| crisaborole            | lavamilast                | tazemetostat      |
| elafibranor            | mirvetuximab              | tesidolumab       |
| eleclazine             | mirvetuximab soravtansine | tezacaftor        |
| epetraborole           | nelonicline               | tonogenchancel-L  |
| follitropin delta      | ozanimod                  | trofinetide       |
| gepotidacin            | pexidartinib              | vosoritide        |
| glecaprevir            | pibrentasvir              | zuretinol acetate |
| guadecitabine sodium   | pinometostat              |                   |
| indimilast             | radalbuvir                |                   |

#### **Sophia V. Fuerst, M.S., M.B.A. DSI President of Nonproprietary Names Division, Drug Safety Institute**

Ms. Fuerst is President of Drug Safety Institute's Nonproprietary (USAN/INN) Names Division. Ms. Fuerst was formerly Director of the USAN Program at the American Medical Association (AMA) and served in various positions during her 18-year tenure with the Program.

She was involved in negotiations between the USAN Council, pharmaceutical manufacturers and foreign nomenclature agencies. From 1986 to 2005 Ms. Fuerst was responsible for reviewing submissions, classifying compounds, creation of new stems when appropriate and approval and adoption of new USAN.

Ms. Fuerst also sat on the World Health Organization (WHO/INN) Committee and served as AMA's senior staff scientist in the area of Drug Nomenclature. Ms. Fuerst holds a B.S. in Biology/Chemistry (pre-med) from St. Joseph's College, an M.S. in Medicinal Chemistry from the University of Chicago and an M.B.A. from Governor's State University in Illinois.